• Non ci sono risultati.

AIOM Giovani domanda agli esperti

N/A
N/A
Info
Scarica
Protected

Academic year: 2022

Condividi "AIOM Giovani domanda agli esperti"

Copied!
8
0
0

Caricamento.... (Visualizza il testo completo ora)

Scarica adesso ( 8 pagine )

Testo completo

(1)

Domande agli esperti

Lucrezia Diodati

U.O. Oncologia Medica 2

AOU Pisa

(2)

Malattia HER 2 +

(3)

Malattia HER 2 +

“The updated network meta-analysis of neoadjuvant therapy for HER-2 positive breast cancer”

Nakashoji A, et al. Cancer Treatmet Reviews 62 (2018) 9-17

(4)

Malattia HER 2 +

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. Von Minckwitz G. et al. N Engl J Med 2019; 380:617-628

(5)

Malattia HER 2 +

Come selezionare le pazienti HER 2 + da candidare a chemioterapia neoadiuvante?

T

ER PgR

Tutte

N

(6)

Malattia HER 2 +

Esiste un sottogruppo di pazienti a cui non proporre TDM-1 adiuvante ?

ypT1a

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. Von Minckwitz G. et al. N Engl J Med 2019; 380:617-628

(7)

Malattia TN

Esiste una chemioterapia neoadiuvante standard per le pazienti con tumore mammario triplo negativo?

Dose dense

BRCA Sali di

platino

(8)

Grazie per l’attenzione

Riferimenti

Scarica adesso ( PDF - 8 pagine - 536.92 KB )

Documenti correlati

Endpoints in oncology clinical trials

However, although ORR, particularly complete response rate, is an endpoint frequently used in studies on neoadjuvant therapy in breast cancer patients, it remains inadequate

What is the optimal current axillary management after NAC?

Methods to minimize the False Negative Rate (FNR) of sentinel lymph node dissection after neoadjuvant chemotherapy for. node positive

Sintesi dei dati di letteratura

We have results from two phase III trials testing CDK4/6 inhibitors in HER+/HER-2 advanced breast cancer patients who progressed on prior endocrine therapy:.

Therapy of breast cancer with molecular targeting agents.

Weekly paclitaxel (PTC) + trastuzumab (T) as first-line therapy of patients (PTS) with HER- 2/neu positive metastatic breast cancer (MBC): a multicenter random- ized phase II

Journal Pre-proof

Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta - analysis of randomized clinical trials.. Crit Rev

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

According to the results of our network meta- analysis, if patients with hormone-receptor-positive, HER2-negative metastatic breast cancer are treated with CDK4/6 inhibitors in

Enhancement of efficacy and selectivity of chemopreventive compounds in human breast cancer cells by using immunoliposomes

Despite the fact that trastuzumab-based treatment strategy has established a milestone in the therapy of HER-2 positive breast cancer with attractive clinical benefits,

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from